BR112012015188A8 - composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese - Google Patents

composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese

Info

Publication number
BR112012015188A8
BR112012015188A8 BR112012015188A BR112012015188A BR112012015188A8 BR 112012015188 A8 BR112012015188 A8 BR 112012015188A8 BR 112012015188 A BR112012015188 A BR 112012015188A BR 112012015188 A BR112012015188 A BR 112012015188A BR 112012015188 A8 BR112012015188 A8 BR 112012015188A8
Authority
BR
Brazil
Prior art keywords
angiogenesis
eye disease
related eye
composition
rhodostomine
Prior art date
Application number
BR112012015188A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012015188A2 (pt
Inventor
Wen-Mei Fu
Woei-Jer Chuang
Yen-Lun Huang
Original Assignee
Univ Nat Cheng Kung
Univ Nat Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Cheng Kung, Univ Nat Taiwan filed Critical Univ Nat Cheng Kung
Publication of BR112012015188A2 publication Critical patent/BR112012015188A2/pt
Publication of BR112012015188A8 publication Critical patent/BR112012015188A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112012015188A 2009-12-23 2010-12-22 composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese BR112012015188A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28962409P 2009-12-23 2009-12-23
PCT/US2010/061738 WO2011079175A1 (en) 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases

Publications (2)

Publication Number Publication Date
BR112012015188A2 BR112012015188A2 (pt) 2016-04-05
BR112012015188A8 true BR112012015188A8 (pt) 2016-08-09

Family

ID=44151942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015188A BR112012015188A8 (pt) 2009-12-23 2010-12-22 composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese

Country Status (14)

Country Link
US (1) US9044436B2 (cg-RX-API-DMAC7.html)
EP (1) EP2515926A4 (cg-RX-API-DMAC7.html)
JP (1) JP5739908B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120130752A (cg-RX-API-DMAC7.html)
CN (1) CN102883738A (cg-RX-API-DMAC7.html)
AR (1) AR079706A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010336475A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012015188A8 (cg-RX-API-DMAC7.html)
CA (1) CA2782796A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007416A (cg-RX-API-DMAC7.html)
NZ (1) NZ600544A (cg-RX-API-DMAC7.html)
RU (1) RU2012131251A (cg-RX-API-DMAC7.html)
TW (1) TWI581801B (cg-RX-API-DMAC7.html)
WO (1) WO2011079175A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2015147616A1 (ko) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
CA2958906C (en) * 2014-08-22 2021-05-04 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
WO2016108669A1 (ko) 2014-12-31 2016-07-07 주식회사 휴온스 Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물
MX382540B (es) * 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
US12304037B2 (en) 2021-11-03 2025-05-20 Aob Products Company Torque driver
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR20250021281A (ko) 2023-08-04 2025-02-12 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물
WO2025033777A1 (ko) 2023-08-04 2025-02-13 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6710030B1 (en) * 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
WO2003042354A2 (en) * 2001-09-04 2003-05-22 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
JP2005529166A (ja) 2002-06-07 2005-09-29 ウィスコンシン アルムニ リサーチ ファウンデーション ペプチドカップリングのための試薬の化学合成
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION

Also Published As

Publication number Publication date
US20110152192A1 (en) 2011-06-23
RU2012131251A (ru) 2014-01-27
JP2013515739A (ja) 2013-05-09
EP2515926A4 (en) 2013-10-09
TW201138801A (en) 2011-11-16
CN102883738A (zh) 2013-01-16
BR112012015188A2 (pt) 2016-04-05
WO2011079175A1 (en) 2011-06-30
US9044436B2 (en) 2015-06-02
KR20120130752A (ko) 2012-12-03
TWI581801B (zh) 2017-05-11
MX2012007416A (es) 2012-07-23
AU2010336475A1 (en) 2012-06-14
NZ600544A (en) 2014-06-27
CA2782796A1 (en) 2011-06-30
AR079706A1 (es) 2012-02-15
JP5739908B2 (ja) 2015-06-24
EP2515926A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
BR112012015188A2 (pt) "composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese"
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112014007675A2 (pt) tratamento de doença articular degenerativa
BR112012006010A2 (pt) composto de glicina
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
BR112015013861A2 (pt) composições e métodos para proteínas de ação prolongada
WO2009137217A8 (en) Therapeutic replenishment and enrichment of ocular surface lubrication
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
ECSP13012609A (es) Composición farmacéutica
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112013005438A2 (pt) "agente para o tratamento de olho ressecado caracterizado por combinar o agonista do receptor de p2y2 e ácido hialurônico ou um sal do mesmo, método para o tratamento de olho ressecado, e uso do agonista do receptor de p2y2, e ácido hialurônico ou um sal do mesmo."
BRPI0507807A (pt) gerenciamento de distúrbios oftalmológicos, incluindo degeneração macular
BRPI0718586A2 (pt) Composto, processo para a sua preparação, composição farmacêutica contendo o mesmo, usos deste e método de tratamento ou prevenção de doenças
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
MX380191B (es) Combinaciones de modalidades para el tratamiento de la diabetes.
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25B Requested transfer of rights rejected

Owner name: NATIONAL CHENG KUNG UNIVERSITY (TW) , NATIONAL TAI